Johnson & Johnson Showcases New Phase 3 Neuropsychiatry Data at ACNP 2026

Johnson & Johnson Showcases New Phase 3 Neuropsychiatry Data at ACNP 2026

By, Admin 14 January 2026

Johnson & Johnson will present 11 new scientific abstracts across depression, schizophrenia, and neuroscience discovery at the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), held January 12–15 in Nassau, Bahamas.

The focus is clear: remission, tolerability, and precision neuroscience.

Why This Matters?

Depression and related disorders remain among the largest unmet needs in medicine.

  • Only 1 in 3 patients achieve remission with first-line antidepressants
  • Treatment resistance rises with each failed therapy
  • Sleep disturbances and anhedonia worsen outcomes

J&J is targeting these gaps with adjunctive therapies, novel mechanisms, and data-driven approaches.

Key Highlights From the ACNP Presentations

CAPLYTA®: New Phase 3 Remission Analyses in MDD

New Phase 3 analyses evaluate CAPLYTA® (lumateperone) as an adjunct to antidepressants in adults with major depressive disorder (MDD).

Key focus areas include:

  • Rates of symptom remission
  • Short- and long-term treatment outcomes
  • Safety and tolerability across patient subgroups

CAPLYTA is already approved for:

  • MDD (adjunctive)
  • Schizophrenia
  • Bipolar depression

SPRAVATO®: Impact on Anhedonia in Treatment-Resistant Depression

Post-hoc analyses from two Phase 3 studies—TRANSFORM-2 and SUSTAIN-2—explore how SPRAVATO® (esketamine) affects anhedonia, one of the most disabling symptoms of depression.

Why this is important:

  • Anhedonia often persists despite standard antidepressants
  • It is strongly linked to relapse and poor functioning

SPRAVATO is approved in 79 markets and has been used by 150,000+ patients worldwide.

Seltorexant vs Quetiapine XR: New Metabolic Tolerability Data

J&J will present new Phase 3 metabolic analyses comparing:

  • Adjunctive seltorexant (investigational)
  • Adjunctive quetiapine XR

The study focuses on patients with MDD and insomnia symptoms. Seltorexant targets the orexin-2 receptor, aiming to:

  • Improve sleep
  • Support mood recovery
  • Avoid next-day sedation and metabolic burden

Beyond Depression: Broader Neuroscience Pipeline

J&J will also present preclinical and translational research covering:

  • Schizophrenia biology and biomarkers
  • AI-enabled neuroscience platforms
  • Novel glutamatergic and synaptic mechanisms
  • Human iPSC-derived CNS models

These efforts support precision medicine in CNS drug development.

Selected Poster Sessions at a Glance

Major Depressive Disorder

  • Remission outcomes with adjunctive lumateperone
  • Metabolic profiles: seltorexant vs quetiapine XR

Treatment-Resistant Depression

  • Short- and long-term effects of esketamine on anhedonia

Schizophrenia

  • Biomarker profiling
  • Antipsychotic exposure in remitted patients

Neuroscience Discovery

  • AI-driven target selection platforms
  • Novel synaptic plasticity mechanisms

Johnson & Johnson’s Strategic Message

According to Bill Martin, PhD, Global Therapeutic Area Head, Neuroscience:

The goal is remission, not partial response. From clinical outcomes to AI-enabled discovery, J&J is redefining standards of care.

Bottom Line

Johnson & Johnson is not betting on a single molecule. It is building:

  • Adjunctive strategies for hard-to-treat depression
  • Biology-driven differentiation
  • Tolerability-first positioning
  • AI-enabled neuroscience discovery

At ACNP 2026, the message is consistent: better remission, fewer trade-offs, smarter neuroscience.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!